Browse studies

Find your next paid study

17 recruiting studies matching your filters

Evaluating the Retinal and Choroidal Microvasculature and Structure Using Multimodal Retinal and Choroidal Imaging in Neurodegenerative Disease: iMIND Research Study

This study aims to develop and evaluate biomarkers using non-invasive optical coherence tomography (OCT) and OCT angiography (OCTA) as well as ultra-widefield …

Alzheimer's DiseaseMild Cognitive ImpairmentParkinson's Disease+12 more

Estimated

~$10 – $750

Duke UniversityNCT03233646

Phase 3

A Two-Part Phase 3b Randomized, Double-Blind, Placebo-Controlled, Followed by Open-Label Extension, Multicenter Study of the Efficacy and Safety of MSC-NTF (NurOwn) in Participants With With Early Symptomatic and Moderate Disease Presentation in Amyotrophic Lateral Sclerosis (ALS)

The goal of this two-part clinical trial is: 1\) to evaluate the safety and efficacy of Debamestrocel - MSC-NTF (NurOwn) compared to placebo in participants w…

Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral Sclerosis

Estimated

~$10 – $8,750

Brainstorm-Cell TherapeuticsNCT06973629

Observational

Comparing the Impact of Video Integration to Traditional Amyotrophic Lateral Sclerosis Visit Communication on Patient and Caregiver Quality of Life

Amyotrophic lateral sclerosis (ALS) is a fatal, rare neurodegenerative disease affecting 30,000 people in the United States. The gold standard of care for peop…

Amyotrophic Lateral Sclerosis (ALS)

Estimated

~$10 – $6,250

Trustees of Dartmouth CollegeNCT07454733

Observational

Examining Interactions Between Persons With ALS and Caregivers

The goal of this clinical trial is to learn about the effect of communicative interaction on verbal communication in people with amyotrophic lateral sclerosis …

Amyotrophic Lateral Sclerosis (ALS)

Estimated

~$10 – $6,250

Penn State UniversityNCT06819124

Phase 1

A Phase 1/2 Study to Evaluate Safety, PK and Biodistribution of an Imaging Agent, 18F-OP-801, After Intravenous Administration to Patients With ALS, Alzheimer's Disease, Multiple Sclerosis, Parkinson's Disease and Healthy Volunteers

This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs. 18F-OP-801 is intended as…

Amyotrophic Lateral Sclerosis (ALS)Parkinson Disease (PD)Alzheimer Disease (AD)+1 more

Estimated

~$10 – $8,750

Ashvattha Therapeutics, Inc.NCT05395624